(S)-tert-Butyl 2-{(azetidine-2-carboxamido)methyl}-4-chlorobenzylcarbamate | 439118-00-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-tert-Butyl 2-{(azetidine-2-carboxamido)methyl}-4-chlorobenzylcarbamate
• 英文别名: tert-butyl N-[[2-[[[(2S)-azetidine-2-carbonyl]amino]methyl]-4-chlorophenyl]methyl]carbamate
• CAS: 439118-00-0
• 化学式: C₁₇H₂₄ClN₃O₃
• 分子量: 353.849
• InChiKey: UQJWBZWBAWJAJV-AWEZNQCLSA-N

物化性质

• 沸点：
  573.2±50.0 °C(Predicted)
• 密度：
  1.216±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  79.5
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S)-tert-Butyl 2-{(azetidine-2-carboxamido)methyl}-4-chlorobenzylcarbamate 在 盐酸 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 生成 (S)-1-((R)-3-Cyclopropyl-2-hydroxy-3-methyl-butyryl)-azetidine-2-carboxylic acid 2-aminomethyl-5-chloro-benzylamide
  参考文献：
  名称：

  Low molecular weight thrombin inhibitors with excellent potency, metabolic stability, and oral bioavailability

  摘要：

  Modification of lead compound 1 by reducing lipophilicity in the P3 group produced a series of low molecular weight thrombin inhibitors with excellent potency in functional assays, metabolic stability, and oral bioavailability. These modifications led to the identification of two optimized compounds, 14 and 16. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.06.030
• 作为产物：
  描述：

  1-azidomethyl-2-(tert-butyloxycarbonylaminomethyl)-5-chlorobenzene 在 哌啶 、 水 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 (S)-tert-Butyl 2-{(azetidine-2-carboxamido)methyl}-4-chlorobenzylcarbamate
  参考文献：
  名称：

  Low molecular weight thrombin inhibitors with excellent potency, metabolic stability, and oral bioavailability

  摘要：

  Modification of lead compound 1 by reducing lipophilicity in the P3 group produced a series of low molecular weight thrombin inhibitors with excellent potency in functional assays, metabolic stability, and oral bioavailability. These modifications led to the identification of two optimized compounds, 14 and 16. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.06.030

文献信息

• Thrombin inhibitors
  申请人：——

  公开号：US20020119992A1

  公开（公告）日：2002-08-29

  Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: 1 or a pharmaceutically acceptable salt thereof, e.g. where R 3 is —CH 2 NH 2 , —CH 2 CH 2 NH 2 , or —CH 2 NHC(O)OC(CH 3 ) 3 .

  该发明的化合物在抑制凝血酶和相关血栓闭塞方面具有以下结构： 1 或其药用可接受的盐，例如其中R 3 为—CH 2 NH 2 ，—CH 2 CH 2 NH 2 ，或—CH 2 NHC(O)OC(CH 3 ) 3 。
• [EN] BENZYLAMINE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS<br/>[FR] DERIVES DE BENZYLAMINE ET LEUR UTILISATION COMME INHIBITEURS DE THROMBINE
  申请人：MERCK & CO INC

  公开号：WO2002050056A1

  公开（公告）日：2002-06-27

  Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, e.g. where R3 is -CH2NH2, -CH2CH2NH2, or -CH2NHC(O)OC(CH3)3.

  本发明的化合物具有以下结构，或其药学上可接受的盐，例如其中R3为-CH2NH2，-CH2CH2NH2或-CH2NHC（O）OC（CH3）3，对于抑制凝血酶和相关的血栓闭塞非常有用。
• Thrombin Inhibitors
  申请人：CHOBANIAN Harry

  公开号：US20150315141A1

  公开（公告）日：2015-11-05

  Compounds of the invention, which may be useful in inhibiting thrombin and associated thrombotic occlusions, have the following structure: or a pharmaceutically acceptable salt thereof, wherein m is 0 or 1; R is a heterocycle, —(CR 8 R 9 ) 1-2 NH 2 , or —(CR 8 R 9 ) 1-2 OH, wherein R 8 and R 9 , each time in which they occur, are independently H, C 1-6 alkyl, —CH 2 F, —CHF 2 , CF 3 or —CH 2 OH; W is a) —CHR 1 R 2 , where R 1 is —C(CH 3 ) 3 , and R 2 is —(CH 2 ) 1-2 OH, b) a 5- or 6-membered unsubstituted or substituted heterocycle having 1 or 2 heteroatoms selected from N and O, wherein substituted heterocycle is substituted with R 3 , c) a 9- or 10-membered unsubstituted or substituted heterocycle having 1 or 2 heteroatoms selected from N, O and S, wherein substituted heterocycle is mono-substituted with R 3 , or disubstituted with R 3 and R 4 , or d) a 3-, 4-, or 5-membered carbocyclic ring which is unsubstituted, mono-substituted with R 3 , di-substituted with R 3 and R 4 , or tri-substituted with R 3 , R 4 and R 5 ; R 3 is —CF 3 , —COOH, —COOR 7 , —C(O)R 6 , —CH(OH)R 6 , —CH 2 R 6 , R 6 , =O, halogen, R 7 , —OH, —NH 2 , or —NHSO 2 R 7 ; and R 10 is H or C 1-6 alkyl.

  本发明的化合物可用于抑制凝血酶和相关的血栓闭塞，具有以下结构：或其药学上可接受的盐，其中m为0或1；R是杂环，-(CR8R9)1-2NH2，或-(CR8R9)1-2OH，其中每次出现时R8和R9独立且为H、C1-6烷基、-CH2F、-CHF2、CF3或-CH2OH；W是a) -CHR1R2，其中R1为-C(CH3)3，R2为-(CH2)1-2OH，b) 1个或2个异原子从N和O中选择的5-或6-成员未取代或取代的杂环，其中取代的杂环取代为R3，c) 1个或2个异原子从N、O和S中选择的9-或10-成员未取代或取代的杂环，其中取代的杂环为单取代的R3，或双取代的R3和R4，或d) 未取代的3-、4-或5-成员碳环，单取代的R3，双取代的R3和R4，或三取代的R3、R4和R5；R3为-CF3、-COOH、-COOR7、-C（O）R6、-CH（OH）R6、-CH2R6、R6、=O、卤素、R7、-OH、-NH2或-NHSO2R7；R10为H或C1-6烷基。
• TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, THEIR PREPARATION AND USE AS SELECTIVE INHIBITORS OF THE CLOTTING FACTORS IIA AND XA
  申请人：The Medicines Company (Leipzig) GmbH

  公开号：EP2655399B1

  公开（公告）日：2017-09-27
• US6515011B2
  申请人：——

  公开号：US6515011B2

  公开（公告）日：2003-02-04